ClinicalTrials.gg
RecruitingNCT05562609I'M-WOMANUpdated Nov 4, 2026

Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk

A Phase 3 interventional study of Tranexamic acid and Placebo in Postpartum Hemorrhage, sponsored by London School of Hygiene and Tropical Medicine. Recruiting at 1 site in Tanzania. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by London School of Hygiene and Tropical Medicine · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 4, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40,000
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.

Planned enrollment
Largest of 50
40,000 · median 198
Started
2024
with 3 others
Phase 3
16 of 50
3 open now
Registered
39th of 50
by date
Lead sponsor
3 of 50
London School of Hygiene and Tropical Medicine

Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one has the largest planned enrollment, is one of 4 that started in 2024, is one of 16 in phase 3, and was the 39th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, or all of them as a file.
02

Study summary

Heavy bleeding after childbirth, known as a postpartum haemorrhage (PPH), causes about 70,000 maternal deaths every year. Tranexamic acid (TXA) is a lifesaving treatment for women with PPH. The I'M WOMAN trial is a research study to see whether giving TXA just before childbirth will stop women developing PPH. The trial will assess the effects of intramuscular (IM) and intravenous (IV) tranexamic acid on PPH, side effects and other important maternal health outcomes.

Read the detailed description

Postpartum haemorrhage (PPH) causes about 70,000 maternal deaths every year. Tranexamic acid (TXA) is a lifesaving treatment for women with PPH. The WOMAN trial recruited over 20,000 women with PPH and found that intravenous (IV) TXA given soon after PPH onset, reduces bleeding deaths by about a third. Early TXA also reduces blood loss in surgery and death due to bleeding after traumatic injury. The World Health Organization recommends that all women with PPH should receive TXA as a first line treatment.

TXA is more effective when given soon after the bleeding starts. Every fifteen minute delay reduces the survival benefit by about 10%. This suggests that giving TXA around the time of childbirth might prevent PPH. Although several clinical trials have examined the effectiveness of TXA for the prevention of PPH, the results are inconclusive. Trials of tranexamic acid for PPH prevention give the trial treatment after cord clamping, which may be too late to prevent bad bleeding in some women, as bleeding tends to happen soon after childbirth. Because PPH only affects a small proportion of births, the healthcare community need good evidence on the balance of benefits and harms in this population before using TXA to prevent PPH.

The I'M WOMAN trial will evaluate the effects of TXA for PPH prevention in women with one or more risk factors for PPH having a vaginal or caesarean birth. The trial will also evaluate the effect of the route of TXA administration. TXA is usually given by slow IV injection. However, recent research shows that TXA is well tolerated and rapidly absorbed after IM injection, achieving therapeutic blood levels within minutes of injection. There may be fewer side effects with IM TXA because peak blood concentrations are lower than with the IV route, as well as practical advantages.

03

Conditions studied

  • Postpartum Hemorrhage

Keywords

  • tranexamic acid
  • postpartum haemorrhage
  • bleeding
  • pregnancy
  • antifibrinolytic
  • intramuscular
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years or older who are admitted to hospital to give birth vaginally or by caesarean section, who have one or more known risk factors for PPH

Exclusion criteria

Exclusion Criteria:

  • Women who have a clear indication or for TXA
  • Women with ongoing antepartum haemorrhage
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40,000 participants (estimated)

Study arms

  • Experimental
    Intramuscular TXA

    1g TXA as 2 x 5 ml IM injections (100mg/ml) and slow IV injection of placebo (1 x 10 ml of 0.9% sodium chloride)

    Drug: Tranexamic acid · Other: Placebo

  • Active comparator
    Intravenous TXA

    1g TXA by slow IV injection and 2 x 5 ml IM injections of placebo

    Drug: Tranexamic acid · Other: Placebo

  • Placebo comparator
    Placebo

    Placebo by 1 x slow 10ml IV injection and 2 x 5 ml IM injections

    Other: Placebo

Interventions

  • Ampoules and packaging for all arms will be identical in appearance.

    Also known as: Cyklokapron

  • OtherPlacebo

    Ampoules and packaging for all arms will be identical in appearance.

    Also known as: (Sodium Chloride 0.9%)

06

What researchers measure

Primary outcomes

  1. Risk of Postpartum haemorrhage

    Clinical assessment: This may be an estimated blood loss of more than 500 mL in vaginal births or more than 1000 ml in caesarean births, or any blood loss sufficient to compromise haemodynamic stability. Haemodynamic instability is based on clinical judgement and assessed using clinical signs (low systolic blood pressure, tachycardia, reduced urine output)

    Time frame: within 24 hours of childbirth

Secondary outcomes

  1. Intraoperative blood loss (caesarean births only)

    Measured by quantifying the amount of blood in sponges and drapes used in surgery and blood loss from suctioning, excluding amniotic fluid

    Time frame: During surgery

  2. Surgery duration (caesarean births only)

    Measured using patient records

    Time frame: During surgery

  3. Intraoperative whole blood/red cell transfusion (caesarean births only)

    Measured using patient records

    Time frame: During surgery

  4. Bleeding related death or near miss (key secondary outcome)

    Any of the following: * Death due to bleeding within 24 hours of birth * Measured blood loss ≥1500ml, comprising intraoperative and drape-measured blood loss up to 2 hours after the end of CS surgery or vaginal birth * Peripartum Hb drop ≥25g/L within 24 hours of birth * Surgical intervention for bleeding (hysterectomy, laparotomy, embolization, uterine compression sutures, arterial ligation) within 24 hours of birth * Blood transfusion of ≥5 units intraoperatively and up to 24 hours after birth * Cardiovascular dysfunction (shock, cardiac arrest, continuous vasoactive drugs, severe hypoperfusion, severe acidosis, cardiopulmonary resuscitation) * Renal dysfunction (oliguria non-responsive to fluids or diuretics, dialysis for acute renal failure, severe acute azotemia)

    Time frame: See description

  5. Drape-measured postpartum blood loss

    Measured using a calibrated obstetric drape starting immediately after vaginal birth or once the women are shifted to a bed in the observation area after CS surgery

    Time frame: 1 hour postpartum, or up to 2 hours if bleeding continues after 1 hour and the woman remains in bed

  6. Blood pressure and heart rate

    Lowest recorded blood pressure reading and associated heart rate measured using patient records

    Time frame: Up to 24 h after birth

  7. Estimated postpartum blood loss

    Time frame: Up to 24 h after birth

  8. Estimated postpartum blood loss (women with clinical diagnosis of PPH only)

    Time frame: At time of PPH diagnosis

  9. Haemoglobin (Hb) or haematocrit (Hct)/packed cell volume (PCV), white cell count, platelet count

    Time frame: Up to 24 h after birth

  10. Interventions for bleeding (uterotonics, non-trial TXA, blood transfusion, surgical and nonsurgical interventions)

    Measured using patient records

    Time frame: Up to 24 h after birth

  11. Nausea, vomiting, dizziness

    Time frame: At removal of calibrated drape

  12. Pain or adverse skin reactions at injection sites

    Time frame: At removal of calibrated drape

  13. Prespecified maternal adverse events (thromboembolic events, seizure, sepsis, organ dysfunction, coagulopathy)

    Measured using patient records

    Time frame: Up to discharge, death or 42 days postpartum, whichever is first.

  14. Other maternal adverse events

    Measured using patient records

    Time frame: Up to discharge, death or 42 days postpartum, whichever is first.

  15. Maternal mortality

    All-cause, cause-specific, narrative; Measured using patient records

    Time frame: Up to discharge, death or 42 days postpartum, whichever is first.

  16. Length of hospital stay

    Measured using patient records

    Time frame: Up to discharge, death or 42 days postpartum, whichever is first.

  17. Days in ICU/HDU

    Measured using patient records

    Time frame: Up to discharge, death or 42 days postpartum, whichever is first.

  18. Transfer to another hospital

    Measured using patient records

    Time frame: Up to discharge, death or 42 days postpartum, whichever is first.

  19. Prespecified neonatal outcomes (breastfeeding, intracranial haemorrhage, pulmonary haemorrhage, bruising, thromboembolic event, seizure, stillbirth/intrapartum death, neonatal death, cause of death, congenital and genetic abnormalities, adverse events)

    Measured using patient records

    Time frame: Up to discharge, death or 42 days postpartum, whichever is first.

07

Study locations

1 of 1 sites recruiting
  • Mbeya Regional Referral Hospital
    Mbeya, Tanzania
    Recruiting
    • Soter Vitalis, MD · Contact
08

References and documents

Publications

  • Larson NJ, Mergoum AM, Dries DJ, Cook A, Blondeau B, Rogers FB. THE ROLE OF TRANEXAMIC ACID IN POSTPARTUM HEMORRHAGE: A NARRATIVE REVIEW. Shock. 2024 Nov 1;62(5):620-627. doi: 10.1097/SHK.0000000000002455. Epub 2024 Aug 20. PubMed 39162220 ↗
  • Brenner A, Shakur-Still H, Chaudhri R, Muganyizi P, Olayemi O, Arribas M, Kayani A, Javid K, Bello A, Roberts I; I'M WOMAN Trial Collaborative Group. Tranexamic acid by the intramuscular or intravenous route for the prevention of postpartum haemorrhage in women at increased risk: a randomised placebo-controlled trial (I'M WOMAN). Trials. 2023 Dec 3;24(1):782. doi: 10.1186/s13063-023-07687-1. PubMed 38044460 ↗

Individual participant data

Plan to share: Yes — The investigators are committed to sharing data for ethical research with justified scientific objectives. Until all planned analyses are completed by the LSHTM CTU Global Health Trials Group, data will be shared through a controlled access approach whereby researchers can make formal applications for data sharing. Afterwards, the anonymised dataset will be shared via the LSHTM CTU Global Health Trials Group data sharing platform at freebird.lshtm.ac.uk. All trial materials including training materials, CRFs and Protocol will be made available on the trial website and team YouTube channel.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Once all planned analyses are completed by the LSHTM CTU Global Health Trials Group following trial completion. Data will be shared indefinitely.

Access criteria: As above

Data sharing details ↗ · freebird.lshtm.ac.uk

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.

Of 20 phase 3 interventional studies under Postpartum Hemorrhage, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 41 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Aug 2025 → Sep 2027 and completion Sep 2025 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Oct 3, 2022
StartActual
Apr 22, 2024
Primary completionEst.
Sep 2027was Aug 2025
CompletionEst.
Oct 2027was Sep 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2025→Sep 2027
Nov 4, 2026
Study completion
Sep 2025→Oct 2027
Nov 4, 2026
Enrollment
30000→40000
Nov 4, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedWomen with ongoing antepartum haemorrhage
Nov 4, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 39162220 ↗
Nov 4, 2026
Secondary outcomes
19 added
What changed in the outcomes
  • AddedIntraoperative blood loss (caesarean births only)Time frame: During surgery
  • AddedSurgery duration (caesarean births only)Time frame: During surgery
  • AddedIntraoperative whole blood/red cell transfusion (caesarean births only)Time frame: During surgery
  • AddedBleeding related death or near miss (key secondary outcome)Time frame: See description
  • AddedDrape-measured postpartum blood lossTime frame: 1 hour postpartum, or up to 2 hours if bleeding continues after 1 hour and the woman remains in bed
  • AddedBlood pressure and heart rateTime frame: Up to 24 h after birth
  • AddedEstimated postpartum blood lossTime frame: Up to 24 h after birth
  • AddedEstimated postpartum blood loss (women with clinical diagnosis of PPH only)Time frame: At time of PPH diagnosis
  • AddedHaemoglobin (Hb) or haematocrit (Hct)/packed cell volume (PCV), white cell count, platelet countTime frame: Up to 24 h after birth
  • AddedInterventions for bleeding (uterotonics, non-trial TXA, blood transfusion, surgical and nonsurgical interventions)Time frame: Up to 24 h after birth
  • AddedNausea, vomiting, dizzinessTime frame: At removal of calibrated drape
  • AddedPain or adverse skin reactions at injection sitesTime frame: At removal of calibrated drape
  • AddedPrespecified maternal adverse events (thromboembolic events, seizure, sepsis, organ dysfunction, coagulopathy)Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
  • AddedOther maternal adverse eventsTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
  • AddedMaternal mortalityTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
  • AddedLength of hospital stayTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
  • AddedDays in ICU/HDUTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
  • AddedTransfer to another hospitalTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
  • AddedPrespecified neonatal outcomes (breastfeeding, intracranial haemorrhage, pulmonary haemorrhage, bruising, thromboembolic event, seizure, stillbirth/intrapartum death, neonatal death, cause of death, congenital and genetic abnormalities, adverse events)Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
Nov 4, 2026
Contact
Study contact changed: i•••@lshtm.ac.uk · •••8283→i•••@lshtm.ac.uk · •••8283. See the current contact
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 39162220 ↗
    Primary completion Aug 2025→Sep 2027
    Study completion Sep 2025→Oct 2027
    Enrollment 30000→40000
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedWomen with ongoing antepartum haemorrhage
    Secondary outcomes 19 added
    What changed in the outcomes
    • AddedIntraoperative blood loss (caesarean births only)Time frame: During surgery
    • AddedSurgery duration (caesarean births only)Time frame: During surgery
    • AddedIntraoperative whole blood/red cell transfusion (caesarean births only)Time frame: During surgery
    • AddedBleeding related death or near miss (key secondary outcome)Time frame: See description
    • AddedDrape-measured postpartum blood lossTime frame: 1 hour postpartum, or up to 2 hours if bleeding continues after 1 hour and the woman remains in bed
    • AddedBlood pressure and heart rateTime frame: Up to 24 h after birth
    • AddedEstimated postpartum blood lossTime frame: Up to 24 h after birth
    • AddedEstimated postpartum blood loss (women with clinical diagnosis of PPH only)Time frame: At time of PPH diagnosis
    • AddedHaemoglobin (Hb) or haematocrit (Hct)/packed cell volume (PCV), white cell count, platelet countTime frame: Up to 24 h after birth
    • AddedInterventions for bleeding (uterotonics, non-trial TXA, blood transfusion, surgical and nonsurgical interventions)Time frame: Up to 24 h after birth
    • AddedNausea, vomiting, dizzinessTime frame: At removal of calibrated drape
    • AddedPain or adverse skin reactions at injection sitesTime frame: At removal of calibrated drape
    • AddedPrespecified maternal adverse events (thromboembolic events, seizure, sepsis, organ dysfunction, coagulopathy)Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
    • AddedOther maternal adverse eventsTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
    • AddedMaternal mortalityTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
    • AddedLength of hospital stayTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
    • AddedDays in ICU/HDUTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
    • AddedTransfer to another hospitalTime frame: Up to discharge, death or 42 days postpartum, whichever is first.
    • AddedPrespecified neonatal outcomes (breastfeeding, intracranial haemorrhage, pulmonary haemorrhage, bruising, thromboembolic event, seizure, stillbirth/intrapartum death, neonatal death, cause of death, congenital and genetic abnormalities, adverse events)Time frame: Up to discharge, death or 42 days postpartum, whichever is first.
    Contact Study contact changed: i•••@lshtm.ac.uk · •••8283→i•••@lshtm.ac.uk · •••8283. See the current contact
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05562609
Collaborators
UNITAID
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Apr 22, 2024
Primary completion
Sep 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Judith Lieber
Contact
imwoman@lshtm.ac.uk
+44 (0)20 7958 8283
Ian Roberts
Contact
+44 (0)20 7958 8128
Judith Lieber
study director · London School of Hygiene and Tropical Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion